Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor
Anna Maria Orengo
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
A.M. Orengo and M. Fabbi contributed equally to this work
Search for more papers by this authorMarina Fabbi
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
A.M. Orengo and M. Fabbi contributed equally to this work
Search for more papers by this authorLoredana Miglietta
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorCristian Andreani
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMilena Bruzzone
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorAndrea Puppo
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorPaolo Cristoforoni
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMaria Grazia Centurioni
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMarina Gualco
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSandra Salvi
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSimona Boccardo
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMauro Truini
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorTiziana Piazza
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSilvana Canevari
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorDelia Mezzanzanica
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorCorresponding Author
Silvano Ferrini
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Tel.: 0039-010-5737-372, Fax: 0039-010-5737-374
Immunotherapy Lab. IST c/o CBA Largo R. Benzi 10 Genova 16132, ItalySearch for more papers by this authorAnna Maria Orengo
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
A.M. Orengo and M. Fabbi contributed equally to this work
Search for more papers by this authorMarina Fabbi
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
A.M. Orengo and M. Fabbi contributed equally to this work
Search for more papers by this authorLoredana Miglietta
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorCristian Andreani
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMilena Bruzzone
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorAndrea Puppo
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorPaolo Cristoforoni
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMaria Grazia Centurioni
Department of Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMarina Gualco
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSandra Salvi
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSimona Boccardo
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorMauro Truini
Department of Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorTiziana Piazza
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for more papers by this authorSilvana Canevari
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorDelia Mezzanzanica
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorCorresponding Author
Silvano Ferrini
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Tel.: 0039-010-5737-372, Fax: 0039-010-5737-374
Immunotherapy Lab. IST c/o CBA Largo R. Benzi 10 Genova 16132, ItalySearch for more papers by this authorAbstract
Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.
References
- 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–49.
- 2 Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009; 36: 112–25.
- 3 Modugno F. Ovarian cancer and high-risk women symposium presenters. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003; 91: 15–31.
- 4 Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra SK. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008; 9: 1076–85.
- 5 Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170–7.
- 6 Sasaroli D, Coukos G, Scholler N. Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 2009; 3: 275–88.
- 7 Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 2009; 11: 60–5.
- 8 Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006; 118: 1750–8.
- 9 Dinarello CA. IL-18: a Th1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103: 11–24.
- 10 Gardella S, Andrei C, Poggi A, Zocchi MR, Rubartelli A. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett 2000; 481: 245–8.
- 11 Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999; 113: 766–72.
- 12 Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, Hanzawa K, Kumagai K, Okamura H. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001; 167: 6568–75.
- 13 Kalina U, Ballas K, Koyama N, Kauschat D, Miething C, Arnemann J, Martin H, Hoelzer D, Ottmann OG. Genomic organization and regulation of the human interleukin-18 gene. Scand J Immunol 2000; 52: 525–30.
- 14 Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002; 98: 873–8.
- 15 Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619–23.
- 16 Nakanishi K, Yoshimoto T, Tsutsui H and Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423–74.
- 17 Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, et al. Cloning of a new cytokine that induces interferon-gamma. Nature 1995; 378: 88–91.
- 18 Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, et al. Cloning of the c DNA for the human IFN--inducing factor, expression in Escherichia coli and studies on the biologic activities of the protein. J Immunol 1996; 56: 4272–9.
- 19 Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S. Defective NK cell activity and Th1 response in IL-18-deficent mice. Immunity 1998; 8: 383–90.
- 20 Heuer JG, McClung CT, Hock RA. Neuroblastoma cells expressing mature IL-18, but not pro-IL-18, induce a strong and immediate antitumour immune response. J Immunother 1999; 22: 324–35.
- 21 Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006; 12: 4265–73.
- 22 Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 2006; 12: 4473–7.
- 23 Martone T, Bellone G, Pagano M, Beatrice F, Palonta F, Emanuelli G, Cortesina G. Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head Neck 2004; 26: 494–503.
- 24 Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G, Purello-Dambrosio F. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 2001; 16: 126–9.
- 25 Günel N, Coskun U, Sancak B, Hasdemir O, Sare M, Bayram O, Celenkoglu G, Ozkan S. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003; 26: 416–21.
- 26 Asakawa M, Kono H, Amemiya H, Matsuda M, Suzuki T, Maki A, Fujii H. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006; 118: 564–70.
- 27 Carrascal MT, Mendoza L, Valcárcel M, Salado C, Egilegor E, Tellería N, Vidal-Vanaclocha F, Dinarello CA. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003; 63: 491–7.
- 28 Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello CA. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417–34.
- 29 Gaggero A, De Ambrosis A, Mezzanzanica D, Piazza T, Rubartelli A, Figini M, Canevari S, Ferrini S. A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene 2004; 23: 7552–60.
- 30 Keller M, Rüegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132: 818–31.
- 31 Lamkanfi M, Dixit VM. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009; 227: 95–105.
- 32
Pagès F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH, Fridman WH.
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumour immune surveillance.
Int J Cancer
1999;
84:
326–30.
10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 33 Sözen S, Coskun U, Sancak B, Bukan N, Günel N, Tunc L, Bozkirli I. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 2004; 51: 25–9.
- 34 Okamoto M, Azuma K, Hoshino T, Imaoka H, Ikeda J, Aizawa H. Correlation of decreased survival and IL-18 in bone metastasis. Intern Med 2009; 48: 763–73.
- 35 Laird SM, Tuckerman EM, Li TC. Cytokine expression in the endometrium of women with implantation failure and recurrent miscarriage. Reprod Biomed Online 2006; 13: 13–23.
- 36 Akahiro J, Konno R, Ito K, Okamura K, Yaegashi N. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol 2004; 9: 42–6.
- 37 Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997; 37: 50–63.
- 38 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436–44.
- 39 Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004; 95: 672–9.
- 40 Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441–52.
- 41 Clark S, McGuckin MA, Hurst T, Ward BG. Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 1994; 39: 100–4.
- 42 Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000; 82: 1138–44.
- 43 Colombo N, Peccatori F, Paganin C, Bini S, Brandely M, Mangioni C, Mantovani A, Allavena P. Immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 1992; 51: 42–6.
- 44 Dinarello CA, Novick D, Rubinstein M, Lonnemann G. Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif 2003; 21: 258–70. Review.
- 45 Fairbanks F, Abrão MS, Podgaec S, Dias JA, Jr, de Oliveira RM, Rizzo LV. Interleukin-12 but not interleukin-18 is associated with severe endometriosis. Fertil Steril 2009; 91: 320–4.
- 46 Oku H, Tsuji Y, Kashiwamura SI, Adachi S, Kubota A, Okamura H, Koyama K. Role of IL-18 in pathogenesis of endometriosis. Hum Reprod 2004; 19: 709–14.
- 47 Arici A, Matalliotakis I, Goumenou A, Koumantakis G, Vassiliadis S, Mahutte NG. Altered expression of interleukin-18 in the peritoneal fluid of women with endometriosis. Fertil Steril 2003; 80: 889–94.
Citing Literature
